T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2651
Westwood Holdings Group
WHG
$184M
| $287K | ﹤0.01% |
16,622
| – | – |
|
|
ATXS
2652
DELISTED
Astria Therapeutics
ATXS
| $286K | ﹤0.01% |
21,810
+2,191
| +11% | +$26.2K |
|
2653
Crescent Capital BDC
CCAP
$417M
| $286K | ﹤0.01% |
20,293
-1,880
| -8% | -$26.7K |
|
2654
First US Bancshares
FUSB
$90.7M
| $286K | ﹤0.01% |
20,414
| – | – |
|
2655
Lantronix
LTRX
$272M
| $286K | ﹤0.01% |
48,722
| – | – |
|
2656
Bain Capital Specialty
BCSF
$821M
| $284K | ﹤0.01% |
20,400
+731
| +4% | +$10.2K |
|
2657
SIGA Technologies
SIGA
$207M
| $284K | ﹤0.01% |
46,344
+3,579
| +8% | +$25.5K |
|
2658
Teekay
TK
$1.06B
| $282K | ﹤0.01% |
31,151
+3,952
| +15% | +$36.4K |
|
2659
Bar Harbor Bankshares
BHB
$681M
| $281K | ﹤0.01% |
9,019
+1,020
| +13% | +$31K |
|
2660
DMC Global
BOOM
$153M
| $280K | ﹤0.01% |
41,727
+13,100
| +46% | +$90.4K |
|
2661
Mama's Creations
MAMA
$790M
| $280K | ﹤0.01% |
20,692
+2,646
| +15% | +$30.4K |
|
2662
Aspen Aerogels
ASPN
$504M
| $279K | ﹤0.01% |
98,299
+21,673
| +28% | +$112K |
|
2663
Quanterix
QTRX
$135M
| $279K | ﹤0.01% |
43,778
-15,000
| -26% | -$93.2K |
|
|
ARDT
2664
Ardent Health
ARDT
$1.55B
| $279K | ﹤0.01% |
31,544
| – | – |
|
2665
Veritone
VERI
$139M
| $278K | ﹤0.01% |
59,674
| – | – |
|
2666
Vipshop
VIPS
$6.8B
| $278K | ﹤0.01% |
15,700
+3,900
| +33% | +$75K |
|
2667
Varex Imaging
VREX
$780M
| $278K | ﹤0.01% |
23,830
+2,508
| +12% | +$29.4K |
|
2668
Hingham Institution for Saving
HIFS
$686M
| $275K | ﹤0.01% |
967
-6
| -0.6% | -$1.71K |
|
2669
MarineMax
HZO
$1.15B
| $275K | ﹤0.01% |
11,325
+1,333
| +13% | +$32.9K |
|
2670
York Water
YORW
$536M
| $275K | ﹤0.01% |
8,609
+1,035
| +14% | +$33.1K |
|
2671
AdvanSix
ASIX
$446M
| $274K | ﹤0.01% |
15,821
+1,869
| +13% | +$32.7K |
|
2672
iShares MSCI Saudi Arabia ETF
KSA
$625M
| $274K | ﹤0.01% |
+7,510
| New | +$291K |
|
|
EU
2673
enCore Energy
EU
$221M
| $273K | ﹤0.01% |
110,029
+12,693
| +13% | +$36.3K |
|
|
FSUN
2674
FirstSun Capital Bancorp
FSUN
$2.02B
| $273K | ﹤0.01% |
7,248
+558
| +8% | +$20.3K |
|
|
AEBI
2675
Aebi Schmidt Holding AG
AEBI
$1.06B
| $273K | ﹤0.01% |
21,552
| – | – |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.